Regular Aspirin Use May Reduce Risk of Dying From Prostate Cancer

Summary includes updated data not in the abstract
For immediate release
January 4, 2016

Contact
Alise Fisher
571-483-1354
alise.fisher@asco.org

ASCO Perspective
“This study suggests there may be yet one more benefit of aspirin, beyond those we’ve already seen in colorectal cancer and heart disease,” said Sumanta Pal, MD, ASCO Spokesperson and moderator of today’s presscast. “While taking aspirin does carry certain side effects that patients should discuss with their physician, it’s intriguing that this low-cost medicine may lower the risk of death from prostate cancer.”

ALEXANDRIA, Va. – A large observational study has found that men who take aspirin regularly may have a lower risk of dying from prostate cancer. Men who took aspirin regularly after their prostate cancer diagnosis were less likely to die from the disease. However, aspirin did not affect the overall incidence of prostate cancer. The study will be presented at the upcoming 2016 Genitourinary Cancers Symposium in San Francisco.

“It is premature to recommend aspirin for prevention of lethal prostate cancer, but men with prostate cancer who may already benefit from aspirin’s cardiovascular effects could have one more reason to consider regular aspirin use,” said lead study author Christopher Brian Allard, MD, Urologic Oncology Fellow at Brigham and Women’s Hospital and Massachusetts General Hospital in Boston, Massachusetts. “When discussing potential benefits of aspirin with their doctors, in terms of both cardiovascular health and risk of prostate cancer death, men should also consider potential risks of regular aspirin use.”

Many studies have looked at medications and supplements that help reduce the risk of death from prostate cancer among healthy men or prolong survival of men with prostate cancer. Prior studies on aspirin and prostate cancer prevention have reported conflicting findings. According to the authors, this is the first study to specifically focus on prevention of lethal cancer, clarifying the role aspirin may play in prevention of advanced disease.

The researchers analyzed data from 22,071 men enrolled in the Physicians’ Health Study. Over 27 years of follow-up, 3,193 men were diagnosed with prostate cancer. Of those, 403 men developed lethal prostate cancer, defined as metastatic disease or death from prostate cancer.
After adjusting for differences in age, race, body mass index, and smoking status, men without a diagnosis of prostate cancer who took aspirin regularly (more than three tablets a week) had a 24% lower risk of developing lethal prostate cancer. However, aspirin did not affect the likelihood of being diagnosed with total prostate cancer, high-grade prostate cancer, or locally advanced prostate cancer.

Among men with prostate cancer, regular aspirin use after diagnosis was associated with a 39% lower risk of dying from prostate cancer. In contrast, use of aspirin before diagnosis did not have a measurable benefit.

“We think that aspirin probably prevents progression of prostate cancer to metastases,” said Dr. Allard. While the biological basis for this protective effect is unknown, preclinical research suggests aspirin may prevent the spread of cancer to the bone.

Dr. Allard and his research team will continue to explore the ways aspirin decreases risk of prostate cancer death. Meanwhile, more research is needed to determine which men in particular would benefit from regular aspirin and what the optimal dose of aspirin is.

The Physicians' Health Study began in 1982 to test the benefits and risks of aspirin and beta carotene in the primary prevention of cardiovascular disease and cancer. Thirty years and more than 400 published research reports later, the study continues. After the original randomized trial ended in 1995, researchers continued to follow study participants through annual questionnaires.

This study received funding from the Prostate Cancer Foundation and the National Institutes of Health/National Cancer Institute.

View the full abstract.

For your readers:

- Guide to Prostate Cancer
- Chemoprevention
- Interactive History of Prostate Cancer Advances

2016 Genitourinary Cancers Symposium News Planning Team
Sumanta Pal, MD, American Society of Clinical Oncology (ASCO); Daniel A. Hamstra, MD, PhD, American Society for Radiation Oncology (ASTRO); and Badrinath R. Konety, MD, MBA, Society of Urologic Oncology (SUO).

Click here to view the disclosures for the News Planning Team.

ATTRIBUTION TO THE 2016 GENITOURINARY CANCERS SYMPOSIUM IS REQUESTED IN ALL NEWS COVERAGE.

About ASCO:

Founded in 1964, the American Society of Clinical Oncology (ASCO) is the world’s leading professional organization representing physicians who care for people with cancer. With more than 35,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds groundbreaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit asco.org. Patient-oriented cancer information is available at CancerNet.